HemoChat is an evidence-based AI medical search tool covering all major clinical domains, powered by 46,298 SNOMED-CT concepts, clinical guidelines, and live PubMed literature.

What medical domains does HemoChat cover?

HemoChat covers all major medical domains including cardiology, oncology, neurology, hematology, pulmonology, endocrinology, gastroenterology, psychiatry, nephrology, rheumatology, musculoskeletal, and more — with 46,298 SNOMED-CT concepts.

Is HemoChat a replacement for clinical judgment?

No. HemoChat is for clinical reference only and is not a substitute for professional medical judgment. Always consult qualified healthcare professionals for medical decisions.

What AI technology does HemoChat use?

HemoChat uses a hybrid GraphRAG + VectorRAG pipeline combining Neo4j knowledge graphs with FAISS vector search and an LLM for answer generation.

Hypertensive heart disease — Clinical Guidelines

Overview

Hypertensive heart disease (HHD) encompasses structural and functional cardiac abnormalities resulting from chronic hypertension, leading to conditions such as left ventricular hypertrophy, myocardial fibrosis, and heart failure 1 5 6.

Diagnosis

Key Diagnostic Criteria: Left ventricular hypertrophy, elevated blood pressure, signs of heart failure (e.g., dyspnea, edema) 1 6 10.

Recommended Tests: Echocardiography for LVH and function assessment, electrocardiogram (ECG) for signs of LVH or ischemia, natriuretic peptides for heart failure 1 18 28.

Grading: Utilize LV wall thickness thresholds (e.g., ≥15 mm for distinguishing from hypertrophic cardiomyopathy) 9.

Management

First-Line Treatments: Lifestyle modifications (diet, exercise, weight management) 1.

Pharmacological Interventions:

- Angiotensin-Converting Enzyme (ACE) Inhibitors: For reducing myocardial remodeling and improving outcomes (e.g., lisinopril) 21. - Angiotensin Receptor Blockers (ARBs): Alternative to ACE inhibitors 15. - Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Empagliflozin for potential benefits in diabetic patients with HHD 7. - Beta-Blockers: To reduce heart rate and myocardial oxygen demand 29.

Adjunctive Treatments:

- Diuretics: For managing fluid overload and hypertension 29. - Calcium Channel Blockers: Particularly useful in African populations with hypertension 26. - Statins: To manage cholesterol and reduce cardiovascular risk 22.

Special Populations

Pregnancy: Management requires careful consideration of teratogenic risks; ACE inhibitors and ARBs are contraindicated 16.

Elderly: Increased focus on minimizing side effects while controlling hypertension and heart failure symptoms 26.

Comorbidities: Diabetes significantly exacerbates cardiovascular complications; SGLT2 inhibitors may offer additional benefits 22.

Key Recommendations

Control Blood Pressure: Target BP <130/80 mmHg in patients with cardiovascular disease (Evidence: Strong 1 21).

Use ACE Inhibitors or ARBs: For reducing myocardial remodeling and improving outcomes in HHD (Evidence: Strong 21).

Consider SGLT2 Inhibitors in Diabetic Patients: To potentially reduce cardiovascular events (Evidence: Moderate 7).

Monitor Left Ventricular Function: Regular echocardiograms to assess LVH and function (Evidence: Moderate 18 28).

Lifestyle Modifications Essential: Diet, exercise, and weight management are foundational (Evidence: Expert opinion 1).

References

1 Che J, Wang Y, Luo L, Tang Y, Huai J, Zeng T et al.. Burden of hypertensive heart disease and its attributable risk factors in 204 countries and territories, 1990-2021: Results from the global burden of disease study 2021. European journal of clinical investigation 2026. link 2 Wang W, Wang S. Nicorandil ameliorates cardiac microcirculation in hypertensive myocardial infarction via LKB1/AMPK signaling activation. Pakistan journal of pharmaceutical sciences 2026. link 3 Tu Q, Gong X, Yuan X, Tang Y, Huang R, Jiang Q et al.. NETs drive myocardial fibrosis in hypertension via an NF-κB/ferroptosis axis. Frontiers in immunology 2025. link 4 Jing H, Cai W, Li X, Zhong X, Dong S, Liu P et al.. Astragaloside IV inhibits the progression of hypertensive heart disease via the RXRA/PPARG/SIRT3 axis. Journal of molecular medicine (Berlin, Germany) 2025. link 5 Jaiswal V, Chowdhury F, Mashkoor Y, Nasir YM, Garimella V, Eynde JVD et al.. Global and Regional Trends in Hypertensive Heart Disease-Related Mortality: Insight from World Health Organization Database. The American journal of cardiology 2025. link 6 González A, López B, Ravassa S, San José G, Latasa I, Butler J et al.. Myocardial Interstitial Fibrosis in Hypertensive Heart Disease: From Mechanisms to Clinical Management. Hypertension (Dallas, Tex. : 1979) 2024. link 7 Abdurrachim D, Teo XQ, Woo CC, Chan WX, Lalic J, Lam CSP et al.. Empagliflozin reduces myocardial ketone utilization while preserving glucose utilization in diabetic hypertensive heart disease: A hyperpolarized . Diabetes, obesity & metabolism 2019. link 8 Kruger R, Schutte AE, Mels CMC, Smith W, van Rooyen JM, Kruger IM et al.. Myocardial triglyceride content in patients with left ventricular hypertrophy: comparison between hypertensive heart disease and hypertrophic cardiomyopathy. Heart, lung & circulation 2017. link 9 Rodrigues JC, Rohan S, Ghosh Dastidar A, Harries I, Lawton CB, Ratcliffe LE et al.. Hypertensive heart disease versus hypertrophic cardiomyopathy: multi-parametric cardiovascular magnetic resonance discriminators when end-diastolic wall thickness ≥ 15 mm. European radiology 2017. link 10 Frustaci A, Francone M, Petrosillo N, Chimenti C. High prevalence of myocarditis in patients with hypertensive heart disease and cardiac deterioration. European journal of heart failure 2013. link 11 Dong X, Sumandea CA, Chen YC, Garcia-Cazarin ML, Zhang J, Balke CW et al.. Augmented phosphorylation of cardiac troponin I in hypertensive heart failure. The Journal of biological chemistry 2012. link 12 Yalçin F, Muderrisoğlu H. Biochemical markers of myocardial remodelling in hypertensive heart disease. International journal of cardiology 2009. link 13 Frielingsdorf J, Genoni M, Hess OM, Flachskampf FA. Do women have impaired regional systolic function in hypertensive heart disease? A 3-dimensional echocardiography study. European journal of echocardiography : the journal of the Working Group on Echocardiography of the European Society of Cardiology 2005. link 14 Marganski WA, De Biase VM, Burgess ML, Dembo M. Demonstration of altered fibroblast contractile activity in hypertensive heart disease. Cardiovascular research 2003. link 15 Varagic J, Frohlich ED. Local cardiac renin-angiotensin system: hypertension and cardiac failure. Journal of molecular and cellular cardiology 2002. link 16 Dean DE, Schultz DL, Powers RH. Asphyxia due to angiotensin converting enzyme (ACE) inhibitor mediated angioedema of the tongue during the treatment of hypertensive heart disease. Journal of forensic sciences 2001. link 17 Kass DA, Chen CH, Talbot MW, Rochitte CE, Lima JA, Berger RD et al.. Ventricular pacing with premature excitation for treatment of hypertensive-cardiac hypertrophy with cavity-obliteration. Circulation 1999. link 18 Frielingsdorf J, Franke A, Kühl HP, Rijcken E, Krebs W, Hess OM et al.. Evaluation of regional systolic function in hypertrophic cardiomyopathy and hypertensive heart disease: a three-dimensional echocardiographic study. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 1998. link70052-5) 19 Pleissner KP, Regitz-Zagrosek V, Krüdewagen B, Trenkner J, Hocher B, Fleck E. Effects of renovascular hypertension on myocardial protein patterns: analysis by computer-assisted two-dimensional gel electrophoresis. Electrophoresis 1998. link 20 Mundhenke M, Schwartzkopff B, Strauer BE. Structural analysis of arteriolar and myocardial remodelling in the subendocardial region of patients with hypertensive heart disease and hypertrophic cardiomyopathy. Virchows Archiv : an international journal of pathology 1997. link 21 Brilla CG, Matsubara L, Weber KT. Advanced hypertensive heart disease in spontaneously hypertensive rats. Lisinopril-mediated regression of myocardial fibrosis. Hypertension (Dallas, Tex. : 1979) 1996. link 22 Grossman E, Rosenthal T. Hypertensive heart disease and the diabetic patient. Current opinion in cardiology 1995. link 23 Nagano R, Masuyama T, Lee JM, Yamamoto K, Naito J, Mano T et al.. Transthoracic Doppler assessment of pattern of left ventricular dysfunction in hypertensive heart disease: combined analysis of mitral and pulmonary venous flow velocity patterns. Journal of the American Society of Echocardiography : official publication of the American Society of Echocardiography 1994. link 24 Sagastagoitia D, Morillas M, Murga N, Boveda J, Molinero E, Rodriguez E et al.. Functional and organic components of diastolic dysfunction in hypertensive heart disease: therapeutic implications. European heart journal 1993. link 25 Neyses L, Vetter H. Isolated myocardial cells: a new tool for the investigation of hypertensive heart disease. Journal of hypertension. Supplement : official journal of the International Society of Hypertension 1990. link 26 Schwartz E, Kofie VY, Rivo M, Tuckson RV. Black/white comparisons of deaths preventable by medical intervention: United States and the District of Columbia 1980-1986. International journal of epidemiology 1990. link 27 Strauer BE. Impaired relaxation of the hypertrophied myocardium is potentiated by angiotensin II. The American journal of medicine 1988. link90204-5) 28 Matsuda Y, Toma Y, Moritani K, Ogawa H, Kohno M, Miura T et al.. Assessment of left atrial function in patients with hypertensive heart disease. Hypertension (Dallas, Tex. : 1979) 1986. link 29 Bush DE, Bulkley BH. Management of patients with hypertension and angina pectoris. The American journal of medicine 1984. link 30 Doi YL, McKenna WJ, Oakley CM, Goodwin JF. 'Pseudo' systolic anterior motion in patients with hypertensive heart disease. European heart journal 1983. link 31 Lowenthal MN. Echocardiographic differentiation of hypertensive heart disease and hypertrophic cardiomyopathy. South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde 1979. link 32 Kino M, Lance VQ, Shahamatpour A, Spodick DH. Effects of age on responses to isometric exercise. Isometric handgrip in noninvasive screening for cardiovascular disease. American heart journal 1975. link90220-3)

Hypertensive heart disease